Last reviewed · How we verify

Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill

Charlotte-Paige Rolle, MD · FDA-approved active Small molecule

Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill is a Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors) Small molecule drug developed by Charlotte-Paige Rolle, MD. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced adults. Also known as: Biktarvy.

This combination pill inhibits HIV reverse transcriptase and integrase to block viral replication and prevent the virus from integrating into host cell DNA.

This combination pill inhibits HIV reverse transcriptase and integrase to block viral replication and prevent the virus from integrating into host cell DNA. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.

At a glance

Generic nameBictegravir / Emtricitabine / Tenofovir Alafenamide Pill
Also known asBiktarvy
SponsorCharlotte-Paige Rolle, MD
Drug classAntiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)
TargetHIV integrase, HIV reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

Bictegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV from inserting its genetic material into human chromosomes. Emtricitabine and tenofovir alafenamide are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that block the enzyme responsible for converting viral RNA into DNA. Together, these three agents target multiple steps of the HIV replication cycle.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill

What is Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill?

Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill is a Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors) drug developed by Charlotte-Paige Rolle, MD, indicated for HIV-1 infection in treatment-naïve and treatment-experienced adults.

How does Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill work?

This combination pill inhibits HIV reverse transcriptase and integrase to block viral replication and prevent the virus from integrating into host cell DNA.

What is Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill used for?

Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill is indicated for HIV-1 infection in treatment-naïve and treatment-experienced adults.

Who makes Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill?

Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill is developed and marketed by Charlotte-Paige Rolle, MD (see full Charlotte-Paige Rolle, MD pipeline at /company/charlotte-paige-rolle-md).

Is Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill also known as anything else?

Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill is also known as Biktarvy.

What drug class is Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill in?

Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill belongs to the Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors) class. See all Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors) drugs at /class/antiretroviral-combination-integrase-inhibitor-nucleoside-reverse-transcriptase-inhibitors.

What development phase is Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill in?

Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill is FDA-approved (marketed).

What are the side effects of Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill?

Common side effects of Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill include Nausea, Diarrhea, Headache, Fatigue, Elevated creatinine.

What does Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill target?

Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill targets HIV integrase, HIV reverse transcriptase and is a Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors).

Related